Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Emergent Biosolutions Inc(EBS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EBS
11/12/2026: EBS (1-star) is currently NOT-A-BUY. Pass it for now.
Emergent Biosolutions is a biotechnology company primarily known for providing medical countermeasures to the U.S. government and commercial healthcare products. While the firm has a long-standing position in the biodefense market, it has faced significant financial and operational challenges, including high debt levels and the erosion of its commercial product margins. The core investment story centers on a difficult turnaround process aimed at stabilizing the balance sheet and narrowing the company's focus. Potential investors should weigh the benefits of its niche government relationships against risks related to execution, debt, and intense market competition. The stock currently suits investors with higher risk tolerance who are monitoring the company's progress in restructuring.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company is currently in a restructuring phase rather than a clear growth trajectory. |
| Momentum investor | Weak fit | The stock has experienced significant downward pressure, failing to provide a positive momentum signal. |
| Value investor | Mixed fit | While valuations appear low, the underlying business risks make it a speculative value play. |
| Dividend investor | Weak fit | The company does not pay a dividend and has prioritized debt management. |
| Low-risk investor | Weak fit | High operational and financial risk makes this unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings driven by government contract news. |
| Valuation risk | Medium / high | Uncertainty in future earnings makes it difficult to establish a stable valuation floor. |
| Competition risk (generic manufacturers) | High | Aggressive competition in the commercial segment erodes margins for key products. |
| Business quality | Medium | The business model is highly dependent on institutional relationships and regulatory compliance. |
| Dividend income | Low / none | There is no dividend income for investors. |
| Execution risk | High | Successful turnaround depends on complex operational restructuring and cost control. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 310.55M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1.1M shares | Beta 2.37 | 52 Weeks Range 4.36 - 14.06 | Updated Date 11/11/2026 |
52 Weeks Range 4.36 - 14.06 | Updated Date 11/11/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.99 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 60.0%
- Active BUY / eligible
- 69 / 115
- 30-Day BUY Count Change
- +29
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 72.7%
- Active BUY / eligible
- 8 / 11
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -15.02% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biodefense | Anthrax and smallpox vaccine sales to the U.S. government. | This segment is steady but heavily reliant on government policy. |
| Commercial Products | Narcan and other therapeutic vaccines. | This is a competitive, high-volume segment facing pricing pressure. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 20.88 | Enterprise Value 643.06M | Price to Sales(TTM) 0.48 |
Enterprise Value 643.06M | Price to Sales(TTM) 0.48 | ||
Enterprise Value to Revenue 1.03 | Enterprise Value to EBITDA 5.24 | Shares Outstanding 51.42M | Shares Floating 49.19M |
Shares Outstanding 51.42M | Shares Floating 49.19M | ||
Percent Insiders 4.2 | Percent Institutions 91.5 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.